Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

NCT03989206 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1700

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-Severe Atopic Dermatitis

Interventions

DRUG: Nemolizumab

Sponsor

Galderma R&D